NewAmsterdam Pharma Company N.V. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 971.67K shares, a 185.52% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 1.97M shares, a 116.86% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 1.12M shares, a 3.42% decline year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 638.94K shares, a 1319.88% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 3.01M shares, a 71.63% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.76M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 971.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 4.71M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 1.97M shares 10-Q · filed 2026-05-07 | 4.07M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 1.12M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | 3.01M shares 10-K · filed 2026-02-18 |
| 2025-09-30 | 638.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 3.05M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 340.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 2.46M shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 909.14K shares 10-Q · filed 2025-05-08 | 2.12M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 1.16M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 1.76M shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 45.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | |
| 2024-03-31 | 546.40K shares 10-Q · filed 2024-05-08 | |
| 2023-12-31 | 200.66K shares 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |